NCT04495829 is a clinical trial of Phorcides Analytical Engine in Refractive Errors, sponsored by American Corneal Consultants.

Who is sponsoring NCT04495829?

NCT04495829 is sponsored by American Corneal Consultants.

What drugs are being tested in NCT04495829?

Interventions in NCT04495829: Phorcides Analytical Engine.

What condition does NCT04495829 study?

NCT04495829 studies Refractive Errors.

Is NCT04495829 still recruiting?

NCT04495829 is currently completed. Last updated 20 July 2023.

Are results published for NCT04495829?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-07-20 · How we verify

NCT04495829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical and Refractive Outcomes After Contoura® Refractive Surgery Planned Using Phorcides Surgery Planning Software

Completed Results posted Last updated 20 July 2023

What this trial tests

trial testing Phorcides Analytical Engine in Refractive Errors in 70 participants. Completed in 21 April 2021.

Timeline

24 July 2020

Primary endpoint
21 April 2021

21 April 2021

Quick facts

Lead sponsor	American Corneal Consultants
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	24 July 2020
Primary completion	21 April 2021
Estimated completion	21 April 2021
Sites	5 locations across United States

Drugs / interventions tested

Phorcides Analytical Engine

Conditions studied

Refractive Errors — all drugs for Refractive Errors →

Sponsor

American Corneal Consultants

Who can join

20 and older, any sex, with Refractive Errors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Residual Refractive Cylinder Primary · 3 months postop

Residual refractive cylinder in diopters

Group	Value	95% CI
Phorcides	0.04	± 0.09

Uncorrected Distance Visual Acuity Secondary · 3 months postop

Uncorrected visual acuity at distance (4-6m)

Group	Value	95% CI
Phorcides	-.11	± 0.06

Residual Refractive Sphere Secondary · 3 months postop

Residual refractive spherical equivalent in diopters

Group	Value	95% CI
Phorcides	0.08	± 0.20

Satisfaction and Vision Secondary · 3 months postop

A questionnaire related to visual quality and satisfaction after surgery

Double vision

Group	Value	95% CI
Phorcides	65
Phorcides	0

Trouble driving at night

Group	Value	95% CI
Phorcides	65
Phorcides	0

Trouble reading

Group	Value	95% CI
Phorcides	65
Phorcides	0

Dryness

Group	Value	95% CI
Phorcides	63
Phorcides	2

Foreign body sensation

Group	Value	95% CI
Phorcides	65
Phorcides	0

Fluctuation in vision

Group	Value	95% CI
Phorcides	65
Phorcides	0

Glare

Group	Value	95% CI
Phorcides	65
Phorcides	0

Halos

Group	Value	95% CI
Phorcides	65
Phorcides	0

Adverse events — posted to ClinicalTrials.gov

Time frame: 3 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phorcides

Serious: 0/70 (0%)

Deaths: 0/70

Other adverse events (1 terms — click to expand)

Reaction	System	Phorcides
Epithelial defect	Eye disorders	—

Data from ClinicalTrials.gov NCT04495829 adverse events section.

Sponsor's own description

The objective of the current study is to prospectively evaluate 3-month clinical outcomes from LASIK performed using the Phorcides surgical planning software with Contoura topography-guided ablation in both eyes of subjects with myopia and myopic astigmatism seeking refractive surgery for distance correction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Refractive Errors

Currently open trials in the same condition.

NCT07460557 — Morphological Characteristics of the Maxillomandibular Region in a 3D Representation and the Refractive Status of the Ey · recruiting
NCT06913491 — Efficacy of PEEK Acuity Versus ETDRS Chart for Assessment of Visual Acuity and Refractive Error · active not recruiting
NCT07001124 — Comparative Efficacy of Duochrome Test Verse +1 Blur Test in Detecting Refracting Error Across Different Ages · NA · active not recruiting
NCT06668246 — Performance of Refractometers With Self-adjusting Lenses Compared to Cycloplegia in Children (REFRALENS) · active not recruiting
NCT05458323 — Cognitive Level Enhancement Through Vision Exams and Refraction · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04495829 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by American Corneal Consultants
Last refreshed: 20 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04495829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing